{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-157374","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.254287+00:00","generated_at":"2026-06-01T05:43:10.690766+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"NewAmsterdam Pharma shareholders approve all proposals at 2024 AGM","bullets":["Quorum of 57.6M shares (64% of eligible) voted; all seven proposals passed.","Proposal 6 (reappointment of Louis Lange): 34.5M For, 13.2M Against, 357k Abstain.","Proposal 5 (appointment of William H. Lewis): 48.1M For, 10.7k Against, 1.2k Abstain.","Adopted 2023 annual accounts, discharged directors, ratified Deloitte as auditor for 2024.","Item 8.01 refiled a license agreement with Menarini omitted from 2023 10-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-157374","json":"https://secwatch.observer/filing/0001193125-24-157374.json","markdown":"https://secwatch.observer/filing/0001193125-24-157374.md","text":"https://secwatch.observer/filing/0001193125-24-157374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524157374/0001193125-24-157374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524157374/d837571d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:43:10.690766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}